Analyzing Pheton (NASDAQ:PTHL) and iSpecimen (NASDAQ:ISPC)

iSpecimen (NASDAQ:ISPC) and Pheton (NASDAQ:PTHL) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, dividends, earnings, profitability and institutional ownership.

Risk and Volatility

iSpecimen has a beta of 1.87, meaning that its share price is 87% more volatile than the S&P 500. Comparatively, Pheton has a beta of 5.4, meaning that its share price is 440% more volatile than the S&P 500.

Insider & Institutional Ownership

13.6% of iSpecimen shares are held by institutional investors. 12.2% of iSpecimen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares iSpecimen and Pheton’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iSpecimen	-343.86%	-531.78%	-147.74%
Pheton	N/A	N/A	N/A

Earnings & Valuation

This table compares iSpecimen and Pheton”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$9.29 million	0.21	-$12.50 million	($7.89)	-0.02
Pheton	$305,215.00	5.89	-$660,000.00	N/A	N/A

Pheton has lower revenue, but higher earnings than iSpecimen.

Analyst Ratings

This is a summary of current ratings and target prices for iSpecimen and Pheton, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1	0	0	0	1.00
Pheton	1	0	0	0	1.00

Summary

Pheton beats iSpecimen on 6 of the 9 factors compared between the two stocks.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.